VRAX vs. NAVB, LSDI, AFIB, SINT, GRI, NMTR, BBLG, NMRD, EVLO, and HSDT
Should you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include Navidea Biopharmaceuticals (NAVB), Lucy Scientific Discovery (LSDI), Acutus Medical (AFIB), Sintx Technologies (SINT), GRI Bio (GRI), 9 Meters Biopharma (NMTR), Bone Biologics (BBLG), Nemaura Medical (NMRD), Evelo Biosciences (EVLO), and Helius Medical Technologies (HSDT). These companies are all part of the "medical" sector.
Navidea Biopharmaceuticals (NYSE:NAVB) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.
Navidea Biopharmaceuticals and Virax Biolabs Group both received 0 outperform votes by MarketBeat users.
In the previous week, Navidea Biopharmaceuticals had 1 more articles in the media than Virax Biolabs Group. MarketBeat recorded 1 mentions for Navidea Biopharmaceuticals and 0 mentions for Virax Biolabs Group. Navidea Biopharmaceuticals' average media sentiment score of 1.44 beat Virax Biolabs Group's score of 0.00 indicating that Virax Biolabs Group is being referred to more favorably in the news media.
Virax Biolabs Group has lower revenue, but higher earnings than Navidea Biopharmaceuticals.
0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Comparatively, 45.1% of Virax Biolabs Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Navidea Biopharmaceuticals has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, Virax Biolabs Group has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.
Summary
Virax Biolabs Group beats Navidea Biopharmaceuticals on 6 of the 9 factors compared between the two stocks.
Get Virax Biolabs Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRAX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Virax Biolabs Group Competitors List
Related Companies and Tools
